IP Library Granted Patent US 9,181,318
Granted Patent B2
US 9,181,318 · App. 12/659,604 · Granted Nov 10, 2015

Method of screening a drug such as insulin secretagogue

Inventor: Inouye Satoshi (Yokohama, JP)
Assignee: JNC Corporation
C07K14/62C12N9/0069C12Q1/66G01N33/502G01N33/74C07K2319/61G01N2333/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,318
App. No.
12/659,604
Granted
Nov 10, 2015
Kind
B2
Abstract

The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.

Claims (37)

1. A method of screening a substance regulating insulin secretion from a cell, which comprises:

contacting a cell transformed with a polynucleotide encoding a fusion protein of preproinsulin and a luciferase with a test substance, and

detecting luminescence of the luciferase to measure a level of insulin secretion,

wherein the luciferase is Gaussia luciferase, and

wherein Gaussia luciferase is a protein of any one of (a) through (c) below:

(a) a protein comprising the amino acid sequence of SEQ ID NO: 8;

(b) a protein consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1 to 10 amino acid residues in the amino acid sequence of SEQ ID NO: 8, and having substantially the same activity as a protein consisting of the amino acid sequence of SEQ ID NO: 8;

(c) a protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 8, and having substantially the same activity as the protein consisting of the amino acid sequence of SEQ ID NO: 8; and,

wherein the preproinsulin consists of a signal peptide of preproinsulin and the polypeptide of any one of (i) through (k) below:

(i) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4;

(j) a polypeptide comprising a polypeptide consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1 to 10 amino acid residues in the amino acid sequence of SEQ ID NO: 4, and having an insulin activity;

(k) a polypeptide comprising a polypeptide consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 4, and having an insulin activity; and,

wherein the signal peptide of preproinsulin is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6.

2. The screening method according to claim 1 , wherein the any one of (e) through (g) below:

(e) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 10;

(f) a polypeptide comprising a polypeptide consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1 to 10 amino acid residues in the amino acid sequence of SEQ ID NO: 10, and having an insulin activity;

(g) a polypeptide comprising a polypeptide consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 10, and having an insulin activity; and,

(h) a polypeptide comprising a polypeptide consisting of an amino acid sequence encoded by a polynucleotide that hybridizes under high stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 9 wherein the high stringent conditions are 5×SSC, 5×Denhardt's solution, 0.5% (w/v) SDS, 50% (v/v) formamide and 50° C., and having an insulin activity.

3. The screening method according to claim 1 , wherein the fusion any one of (m) through (o) below:

(m) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 12;

(n) a polypeptide comprising a polypeptide consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1 to 10 amino acid residues in the amino acid sequence of SEQ ID NO: 12, and having an insulin activity;

(o) a polypeptide comprising a polypeptide consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 12, and having an insulin activity; and,

(p) a polypeptide comprising a polypeptide consisting of an amino acid sequence encoded by a polynucleotide that hybridizes under high stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 11 wherein the high stringent conditions are 5×SSC, 5×Denhardt's solution, 0.5% (w/v) SDS, 50% (v/v) formamide and 50° C., and having an insulin activity.

4. The screening method according to claim 1 , which further comprises the step of detecting luminescence using a CCD camera or a photon counting camera.

5. A method of screening a substance regulating insulin secretion from a cell, which comprises:

contacting a cell transformed with a polynucleotide encoding a fusion protein of preproinsulin and a luciferase with a test substance, and

detecting luminescence of the luciferase to measure a level of insulin secretion,

wherein the luciferase is Gaussia luciferase, and

wherein Gaussia luciferase is a protein of any one of (a) through (c) below:

(a) a protein consisting of the amino acid sequence of SEQ ID NO: 8;

(b) a protein consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1 to 5 amino acid residues in the amino acid sequence of SEQ ID NO: 8, and having substantially the same activity as a protein consisting of the amino acid sequence of SEQ ID NO: 8;

(c) a protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 8, and having substantially the same activity as the protein consisting of the amino acid sequence of SEQ ID NO: 8; and,

wherein the preproinsulin consists of a signal peptide of preproinsulin and the polypeptide of any one of (i) through (k) below:

(i) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4;

(j) a polypeptide comprising a polypeptide consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1 to 10 amino acid residues in the amino acid sequence of SEQ ID NO: 4, and having an insulin activity;

(k) a polypeptide comprising a polypeptide consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 4, and having an insulin activity; and,

wherein the signal peptide of preproinsulin is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2011
From: CHISSO CORPORATION
To: JNC CORPORATION
Reel/Frame 026187/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2010
From: INOUYE, SATOSHI
To: CHISSO CORPORATION
Reel/Frame 024136/0168 →
Priority Claims (1)
JP 2009-063279 · Mar 16, 2009 · national
Continuity (1)
Related Publication 20100240038A1 · Sep 23, 2010